mRNA |
BRD9876:MK-1775 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.049 |
0.7 |
mRNA |
Methotrexate |
GDSC1000 |
pan-cancer |
AAC |
-0.012 |
0.7 |
mRNA |
GSK690693 |
GDSC1000 |
pan-cancer |
AAC |
-0.013 |
0.7 |
mRNA |
SNX-2112:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.014 |
0.7 |
mRNA |
GDC-0941 |
FIMM |
pan-cancer |
AAC |
-0.072 |
0.7 |
mRNA |
tivozanib |
GDSC1000 |
pan-cancer |
AAC |
0.014 |
0.7 |
mRNA |
NVP-BEZ235 |
CTRPv2 |
pan-cancer |
AAC |
0.018 |
0.7 |
mRNA |
BRD-K44224150 |
CTRPv2 |
pan-cancer |
AAC |
-0.032 |
0.7 |
mRNA |
LRRK2-IN-1 |
CTRPv2 |
pan-cancer |
AAC |
-0.015 |
0.7 |
mRNA |
BRD-K75293299 |
CTRPv2 |
pan-cancer |
AAC |
0.031 |
0.7 |